The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. 2016

H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
Department of Immunology, Genetics and Pathology, Rudbeck Laboratory C5:3, Uppsala University, Uppsala, Sweden.

ESSENTIALS: The lectin pathway's MASP-1/2 activates coagulation factors but the trigger of the activation is unknown. MASP-1/2 activation was assessed by quantifying complexes between MASPs and antithrombin/C1-inhibitor. Activated platelets and fibrin were demonstrated to activate MASP-1 and MASP-2 both in vitro and in vivo. These findings may represent a crossroad between the complement and the coagulation systems. CONCLUSIONS BACKGROUND The activated forms of the complement lectin pathway (LP) proteases MASP-1 and MASP-2 are able to cleave the coagulation factors prothrombin, fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor in vitro. In vivo studies also show that MASP-1 is involved in thrombogenesis. OBJECTIVE To clarify the not yet identified mechanisms involved in triggering activation of the LP during thrombotic reactions. METHODS Novel sandwich-ELISAs for detection of complexes between MASP-1 or MASP-2 and the serpins C1 inhibitor (C1-INH) or antithrombin (AT), were used to specifically detect and quantify the activated forms of MASP-1 and MASP-2. RESULTS Activated platelets were shown by flow cytometry to bind Ficolin-1, -2 and -3 but not MBL, which was associated with activation of MASP-1 and MASP-2. We also demonstrated that fibrin and the plasmin-generated fibrin fragment DD in plasma, bind and activate MASP-1 and MASP-2. As demonstrated by the ELISA and SDS-PAGE/Western blotting, the fibrin-associated activation was reflected in a specific inactivation by AT during clotting without the assistance of heparin. In all other cases the MASPs were, as previously reported, inactivated by C1-INH. In systemic lupus erythematosus patients with thrombotic disease and in polytrauma patients, the levels of activated MASP-1 and MASP-2 in complex with both AT and C1-INH were associated with markers of thrombotic disease and contact/coagulation system activation. CONCLUSIONS MASP-1 and MASP-2 are activated during blood clotting. This activation is triggered by activated platelets and by the generation of fibrin during thrombotic reactions in vitro and in vivo, and may represent a novel activation/amplification mechanism in thromboinflammation.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009104 Multiple Trauma Multiple physical insults or injuries occurring simultaneously. Injuries, Multiple,Trauma, Multiple,Wounds, Multiple,Multiple Injuries,Polytrauma,Injury, Multiple,Multiple Injury,Multiple Traumas,Multiple Wound,Multiple Wounds,Polytraumas,Traumas, Multiple,Wound, Multiple
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005260 Female Females

Related Publications

H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
November 2016, Immunological reviews,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
January 2007, Immunobiology,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
January 2021, Genetics and molecular biology,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
September 2002, Immunobiology,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
February 2018, Journal of clinical pathology,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
September 2015, Molecular immunology,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
March 2013, The Journal of biological chemistry,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
May 2014, PLoS neglected tropical diseases,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
September 2002, Immunobiology,
H Kozarcanin, and C Lood, and L Munthe-Fog, and K Sandholm, and O A Hamad, and A A Bengtsson, and M-O Skjoedt, and M Huber-Lang, and P Garred, and K N Ekdahl, and B Nilsson
January 1984, Advances in experimental medicine and biology,
Copied contents to your clipboard!